By Josh White
Date: Tuesday 24 Sep 2024
(Sharecast News) - Hutchmed China announced on Tuesday that its partner Takeda has received approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) to manufacture and market 'Fruzaqla', or fruquintinib, for the treatment of previously-treated metastatic colorectal cancer (CRC).
Japan Approval for FRUZAQLA | 24-Sep-2024 | 08:00 | RNS |
Total Voting Rights | 30-Aug-2024 | 09:30 | RNS |
Update on Fruquintinib for Gastric Cancer in China | 30-Aug-2024 | 07:00 | RNS |
Standard form for notification of major holdings | 22-Aug-2024 | 09:30 | RNS |
LTIP and Share Option Scheme | 06-Aug-2024 | 10:00 | RNS |
Chinese medicine firm employs Cambridge Universi... | 23-Dec-2009 | Guardian |
Joint venture offers food for growth | 09-Oct-2009 | The Scotsman |
Chi-Med unveils maiden profit | 31-Jul-2009 | The Scotsman |
Chi-Med happy with drug tests | 14-Jul-2009 | The Scotsman |
'Watershed' year depends on US drugs trial says ... | 17-Mar-2009 | The Scotsman |
Questor: Hutchison China Meditech | 03-Jul-2007 | Telegraph |
The Week Ahead: Wolseley investors seek calm ami... | 19-Mar-2007 | The Independent |
The Investment Column: Hutchison China MediTech | 21-Nov-2006 | The Independent |
Shares That Sound Good | 02-Jun-2006 | Motley Fool UK |
No recent information was found.
Currency | UK Pounds |
Share Price | 300.00p |
Change Today | 0.000p |
% Change | 0.00 % |
52 Week High | 352.00 |
52 Week Low | 192.40 |
Volume | 87,739 |
Shares Issued | 871.47m |
Market Cap | £2,614.41m |
Beta | 0.00 |
RiskGrade | 226 |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
No dividends found |
Time | Volume / Share Price |
16:36 | 1,000 @ 300.00p |
16:35 | 22,452 @ 300.00p |
16:35 | 1,000 @ 300.00p |
16:35 | 2,402 @ 300.00p |
16:35 | 175 @ 300.00p |
You are here: research